The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases